SOD1 Protein

Overview

SOD1 (Superoxide Dismutase 1) is a copper/zinc-dependent enzyme that catalyzes the dismutation of superoxide radical (O₂⁻) into molecular oxygen (O₂) and hydrogen peroxide (H₂O₂)¹. This enzymatic activity is crucial for cellular defense against oxidative stress, as superoxide radicals are reactive oxygen species (ROS) generated as byproducts of mitochondrial respiration and various cellular processes².^{5CitationPMID 9295279Open reference}4 Mutations in the SOD1 gene were the first genetic cause of amyotrophic lateral sclerosis (ALS) to be identified, accounting for approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases³.^{5CitationPMID 9295279Open reference}5 The discovery of SOD1 mutations in ALS in 1993 established the field of genetic neurodegeneration research and has provided critical insights into the pathogenesis of ALS and related disorders⁴.

Introduction

The superoxide dismutase family comprises three isoforms in humans: SOD1 (copper/zinc SOD, cytosolic), SOD2 (manganese SOD, mitochondrial), and SOD3 (extracellular SOD)⁵. SOD1 is the most abundant isoform and is expressed in virtually all cell types, with particularly high expression in neurons and astrocytes⁶. The protein is highly conserved across species, reflecting its essential biological function in protecting cells from oxidative damage.

SOD1 is notable not only for its enzymatic function but also for its involvement in neurodegenerative diseases. The identification of SOD1 mutations as a cause of familial ALS in 1993 represented a watershed moment in understanding the molecular basis of neurodegeneration⁷. Since then, over 190 mutations in SOD1 have been identified in patients with ALS and related disorders, providing a genetic framework for studying disease mechanisms and developing therapeutic interventions⁸.^{5CitationPMID 9295279Open reference}6

Protein Structure

Primary and Secondary Structure

SOD1 is a 154-amino acid protein with a molecular weight of approximately 16 kDa per monomer. The protein adopts a distinctive Greek key fold consisting of eight antiparallel beta-strands forming a beta-barrel structure⁹. This fold is stabilized by a single intramolecular disulfide bond between cysteine residues at positions 57 and 146 (Cys57-Cys146), which is critical for protein stability¹⁰.

Quaternary Structure and Dimerization

SOD1 functions as a homodimer, with two monomers associate through hydrophobic interactions at the dimer interface¹¹. Each monomer contains:

• Copper binding site (Cu1): Catalytic site where superoxide dismutation occurs

• Zinc binding sites (Zn1, Zn2): Structural site that stabilizes the dimer interface

• Disulfide bond: Cys57-Cys146 maintains structural integrity

The dimeric structure is essential for enzymatic activity, as the dimer interface contributes to substrate binding and proper metal ion coordination¹².

Metal Ion Binding and Catalytic Mechanism

SOD1 requires both copper and zinc ions for full enzymatic activity:

Copper is essential for catalytic activity and participates in the dismutation reaction through a redox cycle:

1. Reduced SOD1-Cu(I) reacts with superoxide to form oxidized SOD1-Cu(II) + O₂

2. Oxidized SOD1-Cu(II) reacts with another superoxide to form reduced SOD1-Cu(I) + H₂O₂

Zinc serves a structural role, stabilizing the protein fold and dimer interface without directly participating in catalysis¹³.

Structural Effects of ALS Mutations

Over 190 ALS-associated mutations affect various aspects of SOD1 structure and function¹⁴:

Normal Physiological Function

Antioxidant Defense

SOD1’s primary function is to catalyze the dismutation of superoxide radical (O₂⁻) into hydrogen peroxide (H₂O₂) and molecular oxygen (O₂)¹⁵:

2 O₂⁻ + 2 H⁺ → O₂ + H₂O₂

This reaction is critical for cellular homeostasis because superoxide radicals are generated continuously as byproducts of normal cellular respiration, particularly from mitochondrial complex I and complex III¹⁶. Unchecked superoxide accumulation leads to:

• Lipid peroxidation

• DNA damage

• Protein oxidation

• Mitochondrial dysfunction

• Ultimately, cell death

Cellular Localization

SOD1 is distributed across multiple cellular compartments¹⁷:

• Cytoplasm: Primary location, highest concentration

• Nucleus: Protects nuclear DNA from oxidative damage

• Mitochondria: Intermembrane space, protects against mitochondrial ROS

• Axons and dendrites: Protects neuronal processes

Role in Neuronal Homeostasis

In the nervous system, SOD1 plays particularly important roles¹⁸:

• Neuronal survival: Protects against oxidative stress-induced apoptosis

• Synaptic function: Maintains synaptic vesicle integrity and neurotransmitter release

• Axonal transport: Supports mitochondrial trafficking along axons

• Myelin maintenance: Protects oligodendrocytes from oxidative damage

Role in Amyotrophic Lateral Sclerosis (ALS)

Genetics of SOD1-Related ALS

SOD1 mutations cause approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases¹⁹. Over 190 distinct mutations have been identified, distributed throughout the gene with clustering in regions important for protein stability and metal binding²⁰.

Common pathogenic mutations include:

Toxic Gain of Function

Mutant SOD1 causes ALS through a toxic gain-of-function mechanism rather than loss of enzymatic activity²¹. The fundamental pathogenic mechanism involves misfolding and aggregation of mutant SOD1 protein, which leads to multiple downstream cellular dysfunctions²².

Pathogenic Mechanisms

Mutant SOD1 triggers neurodegeneration through multiple interconnected mechanisms²³:

1. Protein Misfolding and Aggregation

Mutant SOD1 proteins have reduced thermodynamic stability and tend to misfold, forming toxic oligomers and insoluble aggregates²⁴:

• Misfolded SOD1 accumulates in spinal cord motor neurons

• Aggregates are found in cytoplasmic inclusions (Bunina bodies)

• Toxic oligomers may be more pathogenic than mature aggregates

2. Mitochondrial Dysfunction

Mutant SOD1 directly impairs mitochondrial function²⁵:

• Reduced mitochondrial Complex I activity

• Impaired axonal mitochondrial transport

• Mitochondrial fragmentation and clearance defects

• Energy depletion in motor neurons

3. Axonal Transport Defects

Mutant SOD1 disrupts axonal transport through²⁶:

• Impaired mitochondrial trafficking

• Disrupted neurofilament organization

• Altered microtubule function

• Reduced retrograde transport of signaling endosomes

4. ER Stress and Unfolded Protein Response

Mutant SOD1 triggers endoplasmic reticulum stress²⁷:

• Accumulation of misfolded protein in ER lumen

• Activation of unfolded protein response (UPR)

• CHOP-mediated apoptosis

• Impaired protein folding capacity

5. Excitotoxicity

Mutant SOD1 contributes to glutamate-mediated excitotoxicity²⁸:

• Reduced glutamate transporter (EAAT2) function

• Increased AMPA receptor sensitivity

• Impaired astrocytic glutamate uptake

6. Neuroinflammation

Mutant SOD1 activates glial cells²⁹:

• Microglial activation and proliferation

• Astrogliosis in spinal cord

• Release of pro-inflammatory cytokines

• Non-cell autonomous motor neuron death

flowchart TD
    %% Blue = Triggers/Inputs
    A["Mutant SOD1<br/>Misfolding"]:::blue --> B["Toxic Oligomers"]:::red
    A --> C["Aggregate Formation"]:::red

    %% Orange = Intermediate steps
    B --> D["Mitochondrial<br/>Dysfunction"]:::orange
    B --> E["ER Stress/UPR"]:::orange
    B --> F["Axonal Transport<br/>Defects"]:::orange
    C --> G["Bunina Bodies"]:::red

    %% Outcomes
    D --> H["Energy Depletion"]:::green
    E --> I["CHOP<br/>Apoptosis"]:::green
    F --> J["Motor Neuron<br/>Dysfunction"]:::green
    D --> K["Oxidative Stress"]:::red
    F --> K
    K --> L["Neuroinflammation"]:::red

    %% Downstream
    L --> M["Microglial<br/>Activation"]:::red
    M --> N["Cytokine Release"]:::red
    N --> O["Non-cell Autonomous<br/>Motor Neuron Death"]:::red
    J --> O
    O --> P["ALS Pathology"]:::red

    %% Click links to related pages
    click A "/proteins/sod1" "SOD1 Protein"
    click J "/mechanisms/motor-neuron-vulnerability-als" "Motor Neuron"
    click L "/mechanisms/neuroinflammation" "Neuroinflammation"
    click P "/diseases/amyotrophic-lateral-sclerosis" "ALS"

    %% Color definitions
    classDef blue fill:#0a1929,stroke:#0277bd,stroke-width:2px
    classDef orange fill:#3e2200,stroke:#ef6c00,stroke-width:2px
    classDef green fill:#0e2e10,stroke:#2e7d32,stroke-width:2px
    classDef red fill:#3b1114,stroke:#c62828,stroke-width:2px

Animal Models of SOD1-ALS

Transgenic Mouse Models

SOD1 transgenic mice recapitulate key features of human ALS and have been essential for understanding disease mechanisms³⁰:

Phenotypic characteristics:

• Age-dependent motor neuron loss

• Progressive paralysis

• Muscle denervation

• Mitochondrial pathology

• Glial activation

Non-Mammalian Models

Drosophila melanogaster:

• Express mutant human SOD1 in motor neurons

• Shortened lifespan, motor deficits

• Useful for genetic screens³¹

Zebrafish:

• Motor neuron morphology defects

• Motor axon pathfinding errors

• Useful for drug screening³²

C. elegans:

• Motor neuron degeneration

• Paralysis phenotype

• Rapid generation time for screening³³

SOD1 in Other Neurodegenerative Diseases

Alzheimer’s Disease

SOD1 activity is altered in Alzheimer’s disease³⁴:

• Decreased SOD1 activity in brain tissue

• Increased oxidative stress markers

• Potential for protective therapeutic approaches

Parkinson’s Disease

SOD1 may play a role in Parkinson’s disease³⁵:

• Oxidative stress is a key contributor to dopaminergic neuron loss

• SOD1 mutations are rare but can modify disease risk

• Antioxidant strategies targeting SOD1 are being explored

Frontotemporal Dementia

SOD1 mutations can cause frontotemporal dementia (FTD) without ALS in some cases³⁶:

• Rare SOD1 variants in FTD

• Overlap between ALS and FTD pathogenesis

• TDP-43 pathology in some cases

Huntington’s Disease

SOD1 alterations have been reported in Huntington’s disease³⁷:

• Altered SOD1 expression

• Oxidative stress contribution to pathology

Therapeutic Approaches

Gene Therapy Strategies

1. Gene Silencing

• Antisense oligonucleotides (ASOs) targeting SOD1³⁸

• siRNA delivery to reduce mutant SOD1 expression

• AAV-delivered shRNA constructs

2. Gene Replacement

• Delivery of wild-type SOD1

• Correction of mutations using CRISPR-Cas9

3. Protein-Folding Modulators

• Pharmacological chaperones to stabilize native SOD1 fold

• Small molecules promoting proper folding³⁹

Immunotherapy Approaches

1. Active Vaccination

• Anti-SOD1 antibodies to clear mutant protein

• DNA vaccines expressing wild-type SOD1⁴⁰

2. Passive Immunization

• Monoclonal antibodies against SOD1

• Antibody fragments crossing blood-brain barrier

Small Molecule Therapeutics

1. Antioxidants

• Edaravone (approved for ALS in Japan)

• Coenzyme Q10

• Vitamin E

• N-acetylcysteine⁴¹

2. Mitochondrial Protectants

• MitoQ (mitochondria-targeted antioxidant)

• Creatine

• Olesoxime

3. Anti-aggregates

• Arimoclomol (heat shock protein co-inducer)

• Curcumin derivatives

• Congo red analogs⁴²

4. Anti-excitotoxic

• Riluzole (approved for ALS)

• Ceftriaxone (EAAT2 upregulator)

Cell-Based Therapies

• Stem cell transplantation

• Induced pluripotent stem cell (iPSC)-derived motor neurons

• Mesenchymal stem cells with neurotrophic factors⁴³

Biomarkers for SOD1-ALS

Genetic Biomarkers

• SOD1 mutation status: Predicts disease progression and therapeutic response

• Genetic modifiers: ATXN2, UNC13A influence phenotype⁴⁴

Fluid Biomarkers

Cerebrospinal fluid:

• Mutant SOD1 in CSF (specific to SOD1-ALS)

• Neurofilament light chain (NfL) — disease progression marker

• Chitinase-3-like protein 1 (YKL-40) — neuroinflammation⁴⁵

Blood:

• Circulating mutant SOD1

• Extracellular vesicles containing SOD1

Imaging Biomarkers

• Motor cortex atrophy on MRI

• Diffusion tensor imaging of corticospinal tract

• PET markers of neuroinflammation

History of SOD1 Research

Key Publications

1. Rosen DR, et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62.

2. Deng HX, et al. (1993). Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261:1047-1051.

3. Gurney ME, et al. (1994). Motor neuron degeneration in mice expressing mutant SOD1. Science 264:1772-1775.

4. Cleveland DW, Rothstein JD. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron degeneration in ALS. Nature Reviews Neuroscience 2:806-819.

5. Boillee S, et al. (2006). Onset and progression in ALS determined by mutant SOD1 in microglia. Nature 441:1144-1148.

6. Ilieva H, et al. (2009). Non-cell autonomous toxicity in neurodegenerative disorders. Journal of Cell Biology 187:761-772.

7. Valentine JS, et al. (2005). Copper-zinc superoxide dismutase and ALS. Proceedings of the National Academy of Sciences 102:8251-8253.

8. Kaur SJ, et al. (2016). The SOD1 in ALS: About structure and the effect of pathogenic mutations. Journal of Neurology 263:191-197.

9. Fridovich I. (1995). Superoxide radical and superoxide dismutases. Annual Review of Biochemistry 64:97-112.

10. Renton AE, et al. (2014). State of play in ALS genetics. Nature Reviews Neurology 10:291-307.

11. Mattiazzi M, et al. (2002). Mutant SOD1 causes mitochondrial pathology. Journal of Biological Chemistry 277:29626-29633.

12. Saxena S, et al. (2009). Mutant SOD1 in ER stress in ALS. Journal of Clinical Investigation 119:448-460.

13. De Vos KJ, et al. (2007). Talin binding to mutant SOD1 in ALS. Proceedings of the National Academy of Sciences 104:10040-10045.

14. Smith RA, et al. (2006). Antisense oligonucleotide therapy for SOD1-ALS. Nature Medicine 12:333-337.

15. Johnston JA, et al. (2000). Aggregates of mutant SOD1 in ALS. Journal of Neurology 247:III16-III20.

16. Tainer JA, et al. (1982). Determination and analysis of the 2 A structure of copper,zinc superoxide dismutase. Journal of Molecular Biology 160:181-217.

17. Sturtz LA, et al. (2001). Subcellular localization of SOD1. Journal of Biological Chemistry 276:12084-12091.

18. Feneberg E, et al. (2018). Fluid biomarkers in SOD1-ALS. Brain 141:3063-3074.

19. Maier M, et al. (2006). Anti-SOD1 immunotherapy in ALS. Neuron 54:713-720.

20. Broom HR, et al. (2016). SOD1 folding modulators. Journal of Molecular Biology 428:2304-2316.

21. Pardo CA, et al. (1995). Cu,Zn superoxide dismutase in spinal cord of ALS. Proceedings of the National Academy of Sciences 92:934-938.

22. Lange DJ, et al. (2004). Coenzyme Q10 in ALS. Neurology 63:1656-1661.

See Also

• Amyotrophic Lateral Sclerosis

• Motor Neurons

• Superoxide Dismutase 2 (SOD2 - mitochondrial)

• Superoxide Dismutase 3 (SOD3 - extracellular)

• Oxidative Stress

• Mitochondrial Dysfunction

• Protein Aggregation

• ALS Treatment

• Antisense Oligonucleotide Therapy

External Links

• NCBI Gene: SOD1

• UniProt: P00441

• ALSoD Database

• OMIM: 105400

• RCSB PDB: SOD1

• ALS Therapy Development Institute

• Motor Neuron Disease Association

• Allen Human Brain Atlas - SOD1 Expression

• Allen Mouse Brain Atlas - SOD1

• Allen Cell Type Atlas - SOD1

Pathway Diagram

The following diagram shows the key molecular relationships involving SOD1 Protein discovered through SciDEX knowledge graph analysis:

graph TD
    NRF2["NRF2"] -->|"associated with"| SOD1["SOD1"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| SOD1["SOD1"]
    ALS["ALS"] -->|"associated with"| SOD1["SOD1"]
    PARKINSON_S_DISEASE["PARKINSON'S DISEASE"] -->|"associated with"| SOD1["SOD1"]
    AMYLOID["AMYLOID"] -->|"associated with"| SOD1["SOD1"]
    HUD["HUD"] -->|"regulates"| SOD1["SOD1"]
    CHK2["CHK2"] -->|"phosphorylates"| SOD1["SOD1"]
    HUD["HUD"] -->|"binds"| SOD1["SOD1"]
    IL_6["IL-6"] -->|"associated with"| SOD1["SOD1"]
    HUD["HUD"] -->|"upregulates"| SOD1["SOD1"]
    Chlorogenic_acid["Chlorogenic acid"] -->|"upregulates"| SOD1["SOD1"]
    Tofersen["Tofersen"] -->|"targets"| SOD1["SOD1"]
    Fisetin["Fisetin"] -->|"upregulates"| SOD1["SOD1"]
    NEUROINFLAMMATION["NEUROINFLAMMATION"] -->|"associated with"| SOD1["SOD1"]
    MTORC1["MTORC1"] -->|"phosphorylates"| SOD1["SOD1"]
    style NRF2 fill:#ce93d8,stroke:#333,color:#000
    style SOD1 fill:#4fc3f7,stroke:#333,color:#000
    style ALZHEIMER_S_DISEASE fill:#ef5350,stroke:#333,color:#000
    style ALS fill:#ce93d8,stroke:#333,color:#000
    style PARKINSON_S_DISEASE fill:#ce93d8,stroke:#333,color:#000
    style AMYLOID fill:#ce93d8,stroke:#333,color:#000
    style HUD fill:#4fc3f7,stroke:#333,color:#000
    style CHK2 fill:#4fc3f7,stroke:#333,color:#000
    style IL_6 fill:#ce93d8,stroke:#333,color:#000
    style Chlorogenic_acid fill:#ff8a65,stroke:#333,color:#000
    style Tofersen fill:#ff8a65,stroke:#333,color:#000
    style Fisetin fill:#ff8a65,stroke:#333,color:#000
    style NEUROINFLAMMATION fill:#ce93d8,stroke:#333,color:#000
    style MTORC1 fill:#4fc3f7,stroke:#333,color:#000